Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 16/20 | 0.46 |
| ▸ | PDCD1 | Q15116 | 8/20 | 0.46 |
| ▸ | VSIR | Q9H7M9 | 5/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TERT | O14746 | 1/20 | 0.39 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30393697 | 1.00 | CD274 (0.46) | CD274PDCD1VSIRKDM4EALDH1A1 | |
| SCHEMBL19897677 | 1.00 | CD274 (0.46) | CD274PDCD1VSIRKDM4EALDH1A1 | |
| SCHEMBL19897858 | 0.92 | CD274 (0.46) | CD274PDCD1VSIRKDM4EALDH1A1 | |
| SCHEMBL19897863 | 0.92 | CD274 (0.46) | CD274PDCD1VSIRKDM4EALDH1A1 | |
| SCHEMBL19937791 | 0.90 | CD274 (0.42) | CD274PDCD1VSIRKDM4EALDH1A1 | |
| SCHEMBL24445448 | 0.86 | CYP2D6 (0.49) | CD274KDM4EALDH1A1TERT | |
| SCHEMBL19897514 | 0.84 | CD274 (0.51) | CD274PDCD1VSIRKDM4EALDH1A1 | |
| SCHEMBL19897696 | 0.84 | CD274 (0.54) | CD274PDCD1VSIRALDH1A1 | |
| SCHEMBL19897693 | 0.84 | CD274 (0.54) | CD274PDCD1VSIRALDH1A1 | |
| SCHEMBL30394476 | 0.84 | CD274 (0.54) | CD274PDCD1VSIRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3507284-B1 | BIARYL COMPOUNDS USEFUL AS IMMUNOMODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2022-05-25 | — | — | EP | claimed |
| EP-3507284-A1 | BIARYL COMPOUNDS USEFUL AS IMMUNOMODULATORS | Bristol-Myers Squibb Company (US) | 2019-07-10 | — | — | EP | claimed |
| US-10144706-B2 | Compounds useful as immunomodulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-12-04 | — | — | US | claimed |
| WO-2018044963-A1 | BIARYL COMPOUNDS USEFUL AS IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-03-08 | — | — | WO | claimed |
| US-20180057455-A1 | COMPOUNDS USEFUL AS IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2018-03-01 | — | — | US | claimed |
| EP-3507284-B1 | BIARYL COMPOUNDS USEFUL AS IMMUNOMODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2022-05-25 | — | — | EP | disclosed |
| EP-3507284-A1 | BIARYL COMPOUNDS USEFUL AS IMMUNOMODULATORS | Bristol-Myers Squibb Company (US) | 2019-07-10 | — | — | EP | disclosed |
| US-10144706-B2 | Compounds useful as immunomodulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-12-04 | — | — | US | disclosed |
| WO-2018044963-A1 | BIARYL COMPOUNDS USEFUL AS IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-03-08 | — | — | WO | disclosed |
| US-20180057455-A1 | COMPOUNDS USEFUL AS IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2018-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10144706-B2 | Compounds useful as immunomodulators | CD74, HLA-DRB1, CD47 | CD274 52/4885PDCD1 161/4885VSIR 2484/4885 |
| US-20180057455-A1 | COMPOUNDS USEFUL AS IMMUNOMODULATORS | CD74, HLA-DRB1, CD47 | CD274 52/4885PDCD1 161/4885VSIR 2484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.